Answer
Women of childbearing potential should use adequate contraception during dacomitinib monohydrate (Vizimpro) treatment and for at least 17 days (5 half-lives) after completing treatment.
Sources for this answer
- Vizimpro 15mg film-coated tabletsPfizer Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 5Document updated
Sources checked